Drug Profile
CGX 1321
Alternative Names: CGX1321Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator Curegenix
- Developer Curegenix; University of Alabama
- Class Antineoplastics; Small molecules
- Mechanism of Action PORCN protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastrointestinal cancer; Solid tumours
- Preclinical Ovarian cancer
Most Recent Events
- 02 Jul 2023 CGX 1321 is still in phase I trials for Gastric cancer in China (NCT03507998)
- 02 Jul 2023 CGX 1321 is still in phase I trials for solid tumours in USA and Taiwan (NCT02675946)
- 02 Jun 2023 Pharmacokinetic, Efficacy, Pharmacodynamic and adverse events data from a phase I trial in solid tumours and Gastric cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)